Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Cancer Research and Treatment. 2017;49(4):981-989 
Concurrent chemoradiation for stage III non-small cell lung cancer (NSCLC): from cisplatin alone to cisplatin + etoposide
Lung Cancer. 1994;11:177
Chemoradiotherapy for stage III non-small cell lung cancer
Lung Cancer. 1997;18:112
Neoadjuvant chemoradiotherapy for stage III non-small cell lung cancer
Lung Cancer. 1998;21:S26-S27
Concurrent chemoradiotherapy followed by surgery for advanced stage III non-small cell lung cancer (NSCLC)
Lung Cancer. 1995;13(2):229
A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer
Lung Cancer. 2004;43(3):309-316
Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer
Lung Cancer. 1995;12(1-2):157
Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer
Lung Cancer. 1994;10:S337
Irinotecan/Cisplatin versus Vindesine/Cisplatin versus Irinotecan Alone in Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer. 2001;2(3):180-181
A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma
Lung Cancer. 1992;8(2):138